

**DRUG NAME: Fluorouracil****SYNONYM(S):** 5-FU, 5-Fluorouracil, NSC-19893**COMMON TRADE NAME:** generic available, ADRUCIL®, EFUDEX® CREAM**CLASSIFICATION:** antimetabolite*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Fluorouracil is an analog of the pyrimidine uracil and thus acts as a pyrimidine antagonist.<sup>1</sup> There are three possible mechanisms of action.<sup>2</sup> First, the fluorouracil metabolite fluorodeoxyuridine monophosphate (FdUMP) competes with uracil to bind with thymidylate synthetase (TS) and the folate cofactor.<sup>3</sup> This results in decreased thymidine production and therefore decreased DNA synthesis and repair, and ultimately decreased cell proliferation. Leucovorin (formyltetrahydrofolate, formyl-FH<sub>4</sub>) enhances fluorouracil by stabilizing the binding of FdUMP to TS. Second, the fluorouracil metabolite fluorodeoxyuridine triphosphate (FdUTP) is incorporated into DNA thus interfering with DNA replication.<sup>2</sup> Finally, the fluorouracil metabolite fluorouridine-5-triphosphate (FUTP) is incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.<sup>4</sup> Fluorouracil is cell-cycle specific (S-phase).<sup>3</sup>

**PHARMACOKINETICS:**

Interpatient variability	variations in dihydropyrimidine dehydrogenase (DPD) activity result in differences in toxicity <sup>5</sup> ; see Dihydropyrimidine dehydrogenase deficiency paragraph following Side Effects table	
Oral Absorption	erratic; 28-100%	
Distribution	approximately 22% of total body water; penetrates extracellular fluid and third space fluids (e.g., malignant effusions and ascitic fluid)	
	cross blood brain barrier?	yes
	volume of distribution <sup>6</sup>	8-11 L/m <sup>2</sup>
	plasma protein binding <sup>7</sup>	10%
Metabolism	activated in target cells; 80% degraded in liver by DPD <sup>6</sup>	
	active metabolite(s)	FdUMP, FUTP, and FdUTP
	inactive metabolite(s)	dihydrofluorouracil
Excretion	60-80% excreted as respiratory CO <sub>2</sub> ; 2-3% by biliary system	
	urine	<10% as intact drug <sup>6</sup>
	terminal half life	IV bolus: 8-14 min
	clearance	IV bolus: 350-850 mL/min/m <sup>2</sup> ; dependent on dose, schedule, and route of administration; nonlinear pharmacokinetics due to saturable degradation <sup>6</sup> ; interference with fluorouracil degradation markedly prolongs its half-life <sup>6</sup> continuous infusion: clearance increases
Ethnicity	DPD deficiency: Caucasian (3-5%); African-American 0.1% <sup>8</sup>	

Adapted from standard references<sup>9,10</sup> unless specified otherwise.

**USES:****Primary uses:**

- \*Actinic keratoses (topical fluorouracil)
- \*Bladder cancer
- \*Breast cancer
- \*Colorectal cancer
- \*Gastric cancer
- \*Head and neck cancer
- \*Ovarian cancer
- \*Pancreatic cancer
- \*Prostate cancer
- \*Skin cancer, basal cell (topical fluorouracil)
- \*Health Canada approved indication

**Other uses:**

- Cervical cancer<sup>4</sup>
- Esophageal cancer<sup>4</sup>
- Renal cell cancer<sup>4</sup>
- Skin cancer, Bowen's disease (topical fluorouracil)<sup>11</sup>
- Skin cancer, squamous cell (topical fluorouracil)<sup>11</sup>

**SPECIAL PRECAUTIONS:****Contraindications:**

- history of hypersensitivity reaction to fluorouracil<sup>10</sup>
- relatively contraindicated in patients who have a known hypersensitivity to capecitabine.<sup>12</sup>

**Caution:**

- **Dihydropyrimidine dehydrogenase (DPD) deficiency** may result in life-threatening or fatal toxicity in patients receiving fluorouracil via parenteral or topical administration.<sup>6</sup>
- **Nonlinear pharmacokinetics** result in unpredictable plasma concentrations and toxicity at high doses.<sup>6</sup>
- **Use with caution** in patients who are receiving radiation or who have received high-dose pelvic radiation and in patients previously treated with alkylating agents.<sup>10</sup> These patients may have bone marrow suppression.

**Special populations:**

- **Elderly patients** are at increased risk for developing toxicities, likely due to decreased bone marrow reserve.<sup>6</sup>
- **Female patients** are at increased risk for developing toxicities.<sup>6,13,14</sup>

**Carcinogenicity:** Not yet studied.<sup>3</sup>

**Mutagenicity:** Fluorouracil has been shown to be mutagenic in some bacterial strains.<sup>3</sup> It is clastogenic in mammalian *in vitro* and *in vivo* chromosome tests.

**Fertility:** The effects of fluorouracil on fertility have not been established.<sup>3</sup>

**Pregnancy**<sup>10</sup>: FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

**Breastfeeding** is not recommended due to the potential secretion into breast milk.<sup>9</sup>

**SIDE EFFECTS:**

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important<sup>15</sup>. When placebo-controlled trials are available, adverse events are included if the incidence is  $\geq$  5% higher in the treatment group.

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b>bold, italics</b>	
allergy/immunology	anaphylaxis (rare) <sup>3</sup>
	generalized allergic reactions (rare) <sup>3</sup>
blood/bone marrow/ febrile neutropenia	<b>myelosuppression*</b> : onset: 7-10 days; nadir: 14 days; recovery: 30 days
cardiovascular (arrhythmia)	arrhythmias
	<b>cardiotoxicity*</b> ( $\leq 8\%$ ) <sup>16</sup> ; see paragraph following <b>Side Effects</b> table
	<b>chest pain</b> ( $< 1\%$ ); ranging from mild angina to crushing pain
	CHF (rare) <sup>3</sup>
	hypotension ( $< 1\%$ )
constitutional symptoms	somnolence ( $< 1\%$ )
dermatology/skin	<b>extravasation hazard: irritant</b> <sup>9,10,17</sup>
	For more information on topical application see paragraph after this table.
	alopecia ( $> 10\%$ )
	dermatitis* ( $>10\%$ )
	dry skin and fissuring (1-10%)
	nail changes ( $< 1\%$ ); banding or loss of nails
	<b>palmar-plantar erythrodysesthesia (PPE)*</b> ( $<1\%$ ); see paragraph following <b>Side Effects</b> table
	photosensitivity ( $< 1\%$ )
vein hyperpigmentation ( $< 1\%$ ); proximal to injection sites	
gastrointestinal	<b>emetogenic potential</b> <sup>18</sup> : rare ( $< 10\%$ )
	anorexia ( $> 10\%$ )
	<b>diarrhea*</b> ( $> 10\%$ )
	esophagitis ( $>10\%$ )
	heart burn ( $>10\%$ )
	nausea ( $< 10\%$ )
	<b>stomatitis*</b> ( $> 10\%$ )
	epithelial ulceration (1-10%)
	vomiting ( $< 10\%$ ) <sup>18</sup>
hemorrhage	GI bleeding
hepatic	biliary sclerosis <sup>6</sup>
	hepatic toxicity ( $< 1\%$ )
neurology	acute cerebellar ataxia ( $< 1\%$ ); increased with high doses or intensive regimens; see paragraph following <b>Side Effects</b> table
	neurotoxicities* ( $< 1\%$ )
ocular/visual	excessive lacrimation
	ocular toxicities*; see paragraph following <b>Side Effects</b> table

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b>bold, italics</b>	
pain	headache (< 1%)
pulmonary	dyspnea (< 1%)

Adapted from standard references<sup>9,10</sup> unless specified otherwise.

\*Severity varies with route of administration, refer to the paragraph "Dosing schedule and toxicity".

**Dosing schedule and toxicity:** The spectrum of toxicity associated with fluorouracil treatment varies with dose, schedule, route of administration, and whether the fluorouracil is being used with a biochemical modulator.<sup>6</sup> The most commonly seen toxicities when standard doses are administered in the following schedules and routes are:

- monthly bolus administration<sup>19</sup>: myelosuppression can be dose-limiting
- daily bolus administration for 5 days<sup>19</sup>: diarrhea can be dose-limiting; myelosuppression, stomatitis, ocular, and dermatitis<sup>6</sup>
- continuous infusion given over 24 hours to several weeks<sup>19</sup>: diarrhea, and stomatitis can be dose-limiting; myelosuppression, dermatitis, PPE, neurologic, ocular, and cardiotoxicity<sup>10</sup>
- weekly bolus administration<sup>19</sup>: diarrhea can be dose-limiting; myelosuppression, stomatitis,<sup>6</sup> and ocular<sup>20</sup>
- topical daily<sup>6</sup>: local inflammation

In the event of a **5FU overdose**, appropriate and timely measures to anticipate and implement supportive management of patients at risk for severe 5FU toxicity should be implemented. Refer to BC Cancer Management Guideline: [Management of 5-fluorouracil \(5FU\) infusion overdose](#).

**Oral cryotherapy with bolus doses of fluorouracil:** It is recommended that patients receiving bolus fluorouracil undergo 30 minutes of oral cryotherapy to decrease the incidence and severity of fluorouracil-induced stomatitis.<sup>21</sup> The incidence can be reduced by 50%.<sup>22</sup> Starting 5 minutes before the injection, the patient is asked to place ice chips into their mouth and swish for 30 minutes, replenishing the ice as it melts. This may cause numbness or headaches which subside quickly. This cooling of the oral cavity leads to vasoconstriction resulting in a lower concentration of fluorouracil reaching the oral mucosa.<sup>21</sup> Oral cryotherapy is not used for infusional fluorouracil as this would be very inconvenient. It is also not used for bolus fluorouracil administered in combination with oxaliplatin. This is due to the concern with oxaliplatin and cold related laryngo-dysesthesias.<sup>15</sup>

**Acute cerebellar syndrome** can rarely occur and is characterized by an acute onset of ataxia, dysmetria, dysarthria, and nystagmus that develops weeks to months after beginning treatment.<sup>23</sup> These symptoms usually resolve after discontinuation of fluorouracil.<sup>23</sup> Cerebellar syndrome may be partly explained because fluorouracil crosses the blood-brain barrier, and the highest concentrations are found in the cerebellum.<sup>23</sup> Other rarer neurologic side effects include encephalopathy, optic neuropathy, eye movement abnormalities, focal dystonia, cerebrovascular disorders, parkinsonian syndrome, peripheral neuropathy, and seizures.<sup>23</sup>

**Cardiotoxicity**<sup>16</sup>: Fluorouracil has the second highest incidence of chemotherapy induced cardiotoxicity, after the anthracyclines.<sup>10</sup> The incidence of fluorouracil induced cardiotoxicity can be as high as 8%.<sup>16</sup> Within this group types of cardiotoxicity include<sup>24</sup>:

- electrocardiographic changes, 69%
- angina, 48%
- myocardial infarction, 23%
- acute pulmonary edema, 17%
- arrhythmias, 16%
- elevated cardiac enzymes, 14%
- cardiac arrest and pericarditis, 2%

Coronary vasospasm is thought to be the underlying mechanism of this toxicity.<sup>16,25</sup> Although most patients who experience fluorouracil-induced cardiotoxicity have no previous cardiac problems, history of preexisting coronary artery disease is a risk factor. Other risk factors include route of administration (refer to the Dosing schedule and toxicity paragraph following the Side Effect table) and the use of concurrent radiation or anthracyclines.<sup>16</sup> Most cases of fluorouracil-induced cardiotoxicities resolve after termination of fluorouracil infusion and/or administration of nitrates or calcium channel blockers.<sup>25</sup> Rechallenging these patients remains controversial. If rechallenged, these

patients needs careful observation during drug infusion and may benefit from treatment with calcium channel blockers or nitrates.<sup>25</sup>

**Palmar-plantar erythrodysesthesia (PPE):** also called hand-foot skin reaction, may occur in association with the continuous infusion of fluorouracil.<sup>9</sup> PPE may gradually disappear over 5-7 days after discontinuance of fluorouracil therapy.<sup>3</sup> Although vitamin B<sub>6</sub> (pyridoxine) 50-150 mg orally daily was previously proposed for the prevention of paresthesias<sup>26-28</sup>, current evidence suggests that pyridoxine is not effective.<sup>29,30</sup>

**Dihydropyrimidine dehydrogenase (DPD) deficiency** is a rare, inherited disorder of pyrimidine degradation. The frequency of low or deficient DPD activity in predominantly Caucasian and African-American populations is 3-5% and 0.1%, respectively.<sup>8</sup> For patients with even a partial DPD deficiency, treatment with fluorouracil can lead to life-threatening complications. Fluorouracil clearance is dependent on DPD as fluorouracil is enzymatically inactivated to dihydrofluorouracil by DPD.<sup>31</sup> There is no evidence of fluorouracil degradation in DPD-deficient patients.<sup>32</sup> Toxicities can include severe diarrhea, stomatitis, and myelosuppression.<sup>8</sup> Nausea, vomiting, rectal bleeding, volume depletion, skin changes, and neurologic abnormalities (cerebellar ataxia, changes in cognitive function, changes in the level of consciousness) may also occur.<sup>8</sup> Management should include aggressive supportive care with hemodynamic support, parenteral nutrition, antibiotics, and hematopoietic colony stimulating factors.<sup>8</sup> Tests for the diagnosis of DPD deficiency are not readily available and as a result most cases are diagnosed long after the administration of fluorouracil.<sup>8</sup>

**Ocular toxicity:** Fluorouracil-induced ocular toxicities result primarily from ocular surface problems, such as excessive lacrimation, blurred vision, photophobia, and eye irritation.<sup>19</sup> Excessive lacrimation is the most frequent ocular symptom and can be quite dramatic; it may occur any time during treatment and possibly accompanied with pruritus and burning.<sup>6</sup> Fluorouracil has been found in tear fluid and can cause acute and chronic conjunctivitis leading to tear duct fibrosis. Ocular toxicities can also include epiphora, blepharitis, conjunctivitis, tear duct stenosis, and sclerosing canalculitis. Applying ice packs to the eyes before, during, and for 30 minutes after fluorouracil injection may decrease ocular toxicity.<sup>19</sup>

**Topical application** leads to the following sequence<sup>33</sup>: erythema, usually followed by vesiculation, erosion, ulceration, necrosis, and epithelization. The lower frequency and intensity of activity in adjacent normal skin indicates a selective cytotoxic property. The most frequent local reactions are pain, pruritus, hyperpigmentation, and burning at the application site. Other local reactions include dermatitis, scarring, soreness, and tenderness. Insomnia, stomatitis, suppuration, scaling, swelling, irritability, medicinal taste, photosensitivity, and lacrimation have also been reported.<sup>34</sup>

## INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
cimetidine <sup>35</sup>	delayed, moderate, possible; fluorouracil efficacy and toxicity may be increased	unknown	monitor for fluorouracil toxicity; discontinue cimetidine if necessary
fosphenytoin <sup>35</sup>	delayed, moderate, possible; fosphenytoin efficacy and toxicity may be increased	inhibition of hydantoin metabolism (CYP2C9) by fluorouracil suspected	monitor fosphenytoin plasma levels; observe clinical response when starting or stopping fluorouracil
gemcitabine <sup>36</sup>	fluorouracil efficacy and toxicity may be increased	unknown	some protocols are designed to take advantage of this effect; monitor toxicity closely
leucovorin <sup>19</sup>	increased cytotoxic and toxic effects of fluorouracil	leucovorin stabilizes the bond to thymidylate synthetase	some protocols are designed to take advantage of this effect; monitor toxicity closely
metronidazole <sup>37</sup>	fluorouracil efficacy and toxicity may be increased	metronidazole may decrease the metabolism of fluorouracil	monitor for fluorouracil toxicity

AGENT	EFFECT	MECHANISM	MANAGEMENT
oxaliplatin <sup>38</sup>	no influence on fluorouracil pharmacokinetics		
phenytoin <sup>35</sup>	delayed, moderate, possible; phenytoin efficacy and toxicity may be increased	inhibition of hydantoin metabolism (CYP2C9) by fluorouracil suspected	monitor phenytoin plasma levels; observe clinical response when starting or stopping fluorouracil
thiazides <sup>35</sup> (e.g., chlorthalidone, hydrochlorothiazide)	delayed, moderate, possible; thiazides may prolong fluorouracil-induced leukopenia	unknown	consider alternative antihypertensive therapy
warfarin <sup>39-42</sup>	elevation of anticoagulation parameters (e.g., PTT, INR) and reports of increased bleeding; effect may be delayed <sup>41</sup>	probable inhibition of CYP 2C9 by fluorouracil <sup>43</sup>	monitor INR regularly during therapy (e.g., weekly) <sup>39</sup> ; adjust warfarin dose as needed and increase monitoring if indicated

### SUPPLY AND STORAGE:

#### **Topical:**

Valeant Canada Limited supplies fluorouracil 5% in a vanishing cream base of white petrolatum, stearyl alcohol, propylene glycol, polysorbate 60, and parabens. Store at room temperature. Protect from light.<sup>44</sup>

#### **Injection:**

Sandoz Canada Inc. supplies fluorouracil as a sterile solution without preservative in 500 mg single-dose and 5000 mg pharmacy bulk latex-free vials. Store at room temperature. Protect from light.<sup>45</sup>

Hospira Healthcare Corporation supplies fluorouracil as a sterile solution without preservative in 5000 mg pharmacy bulk vials. Store at room temperature. Protect from light.<sup>46</sup>

**For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.**

### SOLUTION PREPARATION AND COMPATIBILITY:

**For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.**

**Additional information:** Slight discolouration does not affect potency or safety.<sup>47</sup> Darker yellow discolouration indicates greater decomposition so dark yellow solutions may need to be discarded.<sup>47</sup> Crystals that have formed in the solution can be redissolved by warming and shaking.<sup>47</sup>

### PARENTERAL ADMINISTRATION:

BC Cancer administration guideline noted in **bold, italics**

Subcutaneous	not used due to corrosive nature
Intramuscular	not used due to corrosive nature
<b>* Direct intravenous</b>	<b><i>over 2-4 minutes</i></b> <sup>48,49</sup>
<b>* Intermittent infusion</b>	<b><i>can be used (e.g., dilute in 50 mL and infuse for up to 15 minutes)</i></b> <sup>10</sup>

BC Cancer administration guideline noted in **bold, italics**

<b>*Continuous infusion</b>	<b>over 24 hours or greater; may be given via an ambulatory infusion device</b>
<b>Intraperitoneal<sup>50</sup></b>	<b>15 mg/kg and 50 mEq sodium bicarbonate to 1000 mL 1.5% dextrose dialysis solution; dwell for 23 hours then drain for one hour</b>
Intrapleural	no information found
Intrathecal <sup>1</sup>	contraindicated due to neurotoxicity
Intra-arterial <sup>1</sup>	hepatic artery
Intravesical <sup>3</sup>	portal vein infusion

\*Doses prescribed for continuous infusion can be FATAL when given as direct intravenous or intermittent infusion.

**TOPICAL ADMINISTRATION:**

The cream is applied twice daily, preferably with a nonmetal applicator or glove. If the cream is applied with fingertips, the hands should be washed immediately afterwards.<sup>34</sup> Apply with care near the eyes, mouth and nose. An occlusive dressing is not essential, and may increase the incidence of inflammatory reactions in adjacent normal skin. Therapy is usually continued until the inflammatory reaction reaches the erosion, necrosis and ulceration stage (2-4 weeks), after which healing occurs over 4-8 weeks. While the patient is undergoing topical 5-FU therapy, consideration can be given to curettage, wound excision and removal of pathological tissue.<sup>34</sup> Patients should avoid prolonged exposure to ultraviolet light while under treatment as the intensity of the reaction may be increased.

**DOSAGE GUIDELINES:**

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

**Adults:**BC Cancer usual dose noted in **bold, italics**

Cycle Length:

*Intravenous:*

**1 week<sup>51,52</sup>:** **1000 mg/m<sup>2</sup> IV over 24 hours for 2 consecutive days**  
starting on day 1  
(total dose per cycle 2000 mg/m<sup>2</sup>)

(maximum dose is 5000 mg/48 h)

**2 weeks<sup>53-57</sup>:** **400 mg/m<sup>2</sup> IV for one dose on day 1 immediately followed by 2400-3000 mg/m<sup>2</sup> IV over 46 hours**  
(total dose per cycle 2800-3400 mg/m<sup>2</sup>)

**3 weeks<sup>58-65</sup>:** **500-600 mg/m<sup>2</sup> IV for one dose on day 1**  
(total dose per cycle 500-600 mg/m<sup>2</sup>)

**3 weeks<sup>66</sup>:** **1000 mg/m<sup>2</sup> IV over 24 hours for 3 consecutive days**  
starting on day 1  
(total dose per cycle 3000 mg/m<sup>2</sup>)

<b>4 weeks<sup>67,68</sup>:</b>	<b>425 mg/m<sup>2</sup> IV once daily for 5 consecutive days</b> starting on day 1 (total dose per cycle 2125 mg/m <sup>2</sup> )
<b>4 weeks<sup>69,70</sup>:</b>	<b>when given as a dose-dense regimen with filgrastim (G-CSF) support:</b> <b>500 mg/m<sup>2</sup> IV for one dose on days 1 and 8</b> (total dose per cycle 1000 mg/m <sup>2</sup> )
<b>4 weeks<sup>71-73</sup>:</b>	<b>500-600 mg/m<sup>2</sup> IV for one dose on days 1 and 8</b> (total dose per cycle 1000-1200 mg/m <sup>2</sup> )
<b>4 weeks<sup>74-77</sup>:</b>	<b>when given as a dose-dense regimen with filgrastim (G-CSF) support:</b> <b>500 mg/m<sup>2</sup> IV for one dose on days 1 and 15</b> (total dose per cycle 1000 mg/m <sup>2</sup> )
<b>4 weeks<sup>78,79</sup>:</b>	<b>1000 mg/m<sup>2</sup> IV over 24 hours for 4 consecutive days</b> starting on day 1 (total dose per cycle 4000 mg/m <sup>2</sup> )
<b>6 weeks<sup>80,81</sup>:</b>	<b>400-500 mg/m<sup>2</sup> IV on day 1, 8, 15 and 22</b> (total dose per cycle 1600-2000 mg/m <sup>2</sup> )
<b>6 weeks<sup>81</sup>:</b>	<b>1000 mg/m<sup>2</sup> IV over 24 hours for 4 consecutive days</b> starting on day 1 (total dose per cycle 4000 mg/m <sup>2</sup> )
<i>Concurrent radiation<sup>82-89</sup>:</i>	can be used with variable schedules and dosing; specific treatment protocols must be consulted; see Special Precautions regarding patients who have received high-dose pelvic radiation
<i>Dosage in myelosuppression:</i>	modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix "Dosage Modification for Myelosuppression"
<i>Dosage in obesity<sup>9</sup>:</i>	if patient is obese or there has been a spurious weight gain because of edema, ascites or other form of abnormal fluid retention, the ideal weight or estimated lean body mass should be used
<i>Dosage in renal failure:</i>	no adjustment required
<i>Dosage in hepatic failure:<sup>90-94</sup></i>	standard doses have been used in some patients with elevated bilirubin; may consider 50% dose reduction for starting doses or omit dose for bilirubin >85 micromol/L or AST >180 units/L
<i>Dosage in dialysis:</i>	hemodialysis: give ½ dose <sup>7</sup> ; administer dose following hemodialysis <sup>10</sup>  chronic ambulatory peritoneal dialysis (CAPD): no data <sup>7</sup>  continuous renal replacement therapy (CRRT): give full dose <sup>95</sup>



*Topical*<sup>33</sup>: apply twice daily x 2-4 weeks

**Children:**

*Intravenous*<sup>32</sup>: 500 mg/m<sup>2</sup> IV once or daily x 5

800-1200 mg/m<sup>2</sup> IV over 24-120 h

*Topical*<sup>34</sup>: use and dose as determined by physician

**REFERENCES:**

- Dorr RT, Von-Hoff DD. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, Connecticut: Appleton & Lange; 1994. p. 27-28,123.
- van der Wilt CL, Marinelli A, Pinedo HM, et al. The effects of different routes of administration of 5-fluorouracil on thymidylase synthase inhibition in the rat. *Eur J Cancer* 1995;31A(5):754-760.
- McEvoy GK, editor. AHFS 2006 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists. p. 1052-1056.
- McEvoy GK, editor. AHFS 2005 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists. p. 1020-1025.
- van Kuilenburg AB, Muller EW, Haasjes J, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. *Clin Cancer Res* 2001;7(5):1149-53.
- Chabner BA, Longo DL. Cancer Chemotherapy and Biotherapy. 3rd ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2001.
- Aronoff GR, Berns JS, Brier ME, Golper TA, et al. Drug Prescribing in Renal Failure. 4th ed. ; 1999. p. 74.
- Rose BD editor. Enterotoxicity of chemotherapeutic agents. UpToDate ed. Waltham, Massachusetts: UpToDate®; 2006.
- Mayne Pharma Canada Inc. Fluorouracil product monograph. Montreal, Quebec; 2003.
- Rose BD editor. Fluorouracil. UpToDate ed. Waltham, Massachusetts: UpToDate®; 2006.
- Rose BD editor. Treatment and prognosis of cutaneous squamous cell carcinoma. UpToDate ed. Waltham, Massachusetts: UpToDate®; 2006.
- Hoffman-La Roche Limited. XELODA® product monograph. Mississauga, Ontario; 31 July 2002.
- Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. *J Clin Oncol* 2002;20(6):1491-1498.
- Chansky K, Benedette J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal cancer. *Cancer* 2005;103(6):1165-71.
- Sharlene Gill MD. Personal communication. BC Cancer Agency Gastrointestinal Tumour Group; April 2006.
- Rose BD editor. Cardiotoxicity in patients receiving chemotherapy. UpToDate ed. Waltham, Massachusetts: UpToDate®; 2006.
- Teta JB, O'Connor L. Local tissue damage from 5-fluorouracil extravasation (letter). *Oncol Nurs Forum* 1984;11(77).
- BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; May 1999.
- Finley RS, Balmer CB. Concepts in Oncology Therapeutics. 2nd ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 1998.
- Petrelli N, Douglass HD, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. *J Clin Oncol* 1991;7(10):1419-1426.
- Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. *Cancer* 2004;Supplement:2026-2046.
- Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral candidiasis for patients with cancer receiving treatment [Systematic Review]. *Cochrane Database* 2006.
- Rose BD editor. Neurologic complications of cancer chemotherapy. UpToDate ed. Waltham, Massachusetts: UpToDate®; 2006.
- Saif MW, Szabo E, Grem JL, et al. The clinical syndrome of fluorouracil cardiotoxicity (Abstract). *Proc Am Soc Clin Oncol* 2001;20:404a.
- Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. *J Clin Oncol* 2005;23(30):7685-7696.
- Vukelja SJ, Lombardo FA, James WD, et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. *Ann Intern Med* 1989;111(8):688-689.
- Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. *Invest New Drugs* 1990;8(1):57-63.
- Lauman MK, Mortimer J. Effect of Pyridoxine on the Incidence of Palmar Plantar Erythroderma (PPE) in Patients Receiving Capecitabine. *Proceedings of the American Society of Clinical Oncology* 2001;20(Part 1):392a (abstract 1565).

29. Kang Y, Lee SS, Yoon DH, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. *J Clin Oncol* 2010;28(24):3824-3829.
30. von Gruenigen V, Frasure H, Fusco N, et al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. *Cancer* 2010;116(20):4735-4743.
31. DeVita VT, Hellman S, Rosenberg S editors. *Cancer Principles and Practice on Oncology*. 6th ed. Philadelphia, Pennsylvania: Lippincott Williams and Wilkins; 2001.
32. Pizzo P, Poplack D. *Principles and Practice of Pediatric Oncology*. 4th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2002. p. 246.
33. Repchinsky C, editor. *Compendium of Pharmaceuticals and Specialties*. Ottawa, Ontario: Canadian Pharmacists Association; 2005.
34. Valeant Canada Limited. EFUDEX® product monograph. Montreal, Quebec; 2005.
35. Tatro DS editor. *Fluorouracil. Drug Interactions Facts on Disc* ed. St. Louis, Missouri: Facts and Comparisons; 2005.
36. Rose BD editor. *Fluorouracil/Gemcitabine. UpToDate* ed. Waltham, Massachusetts: UpToDate®; 2006.
37. Rose BD editor. *Fluorouracil/Metronidazole. UpToDate* ed. Waltham, Massachusetts: UpToDate®; 2006.
38. Joel SP, Richards F, Seymour M. Oxaliplatin (L-OHP) does not influence the pharmacokinetics of 5-fluorouracil (5-FU)(Abstract 748). *Proc Am Soc Clin Oncol* 2000;19:192a.
39. Kolesar J, Johnson C, Freeberg B. Warfarin-5-FU interaction: a consecutive case series. *Pharmacotherapy* 1999;19(12):1445-1449.
40. Saif MW. An adverse interaction between warfarin and fluoropyrimidines revisited. *Clinical Colorectal Cancer* 2005;5(3):175-180.
41. Davis DA, Fugate SE. Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-fluorouracil therapy. *Pharmacotherapy* 2005;25(3):442-447.
42. Lexicomp Online®: Interactions (database on the Internet). Fluorouracil. Lexi-Comp Inc., Available at: <http://online.lexi.com>. Accessed 16 June 2015.
43. MICROMEDEX® 2.0 Drug Interactions (database on the Internet). Fluorouracil. Truven Health Analytics, updated periodically. Available at: <http://www.micromedexsolutions.com/>. Accessed 16 June 2015.
44. Valeant Canada Limited. EFUDEX® product monograph. Montreal, Quebec; 15 December 2004.
45. Sandoz Canada Inc. Fluorouracil injection® product monograph. Boucherville, Quebec; 4 March 2009.
46. Hospira Healthcare Corporation. Fluorouracil injection® product monograph. Saint-Laurent, Quebec; 7 June 2007.
47. Trissel L. *Handbook on Injectable Drugs*. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 2005. p. 613-622.
48. Glimelius B, Jakobsen A, Graf W, et al. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. *Eur J Cancer* 1998;34(5):674-678.
49. Larsson PA, Carlsson G, Gustavsson B, et al. Different intravenous administration techniques for 5-Fluorouracil pharmacokinetics and pharmacodynamic effects. *Acta Oncol* 1996;35(2):207-212.
50. BC Cancer Agency Gastrointestinal Tumour Group. (UGIFUIP) BCCA Protocol Summary for the Chemotherapy of Pseudomyxoma Peritonei Using Intraperitoneal Using Mitomycin and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2006.
51. BC Cancer Agency Gastrointestinal Tumour Group. (GIFUC) BCCA Protocol Summary for Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder Carcinoma and Cholangiocarcinoma) and Metastatic Anal Cancer Using Infusional Fluorouracil and Cisplatin. Vancouver, British Columbia: BC Cancer Agency; 2005.
52. BC Cancer Agency Gastrointestinal Tumour Group. (GIFUINF) BCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Adenocarcinoma Using Infusional Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2006.
53. BC Cancer Agency Gastrointestinal Tumour Group. (GIFOLFIRI) BCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil and Folic Acid (Leucovorin). Vancouver, British Columbia: BC Cancer Agency; 2006.
54. BC Cancer Agency Gastrointestinal Tumour Group. (UGIAJFOLFOX) BCCA Protocol Summary for Adjuvant Combination Chemotherapy for Stage III Colon Cancer Using Oxaliplatin, 5-Fuorouracil and Folic Acid (Leucovorin). Vancouver, British Columbia: BC Cancer Agency; 2005.
55. BC Cancer Agency Gastrointestinal Tumour Group. (UGIFFIRB) BCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, Folic Acid (Leucovorin) and Bevacizumab. Vancouver, British Columbia: BC Cancer Agency; 2006.
56. BC Cancer Agency Gastrointestinal Tumour Group. (UGIFFOXB) BCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, 5-Fluorouracil and Folic Acid (Leucovorin) and Bevacizumab. Vancouver, British Columbia: BC Cancer Agency; 2006.
57. BC Cancer Agency Gastrointestinal Tumour Group. (UGIFOLFOX) BCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, 5-Fuorouracil and Folic Acid (Leucovorin). Vancouver, British Columbia: BC Cancer Agency; 2005.
58. BC Cancer Agency Breast Tumour Group. (UBRAJCAF) BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Cyclophosphamide, Doxorubicin and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2004.
59. BC Cancer Agency Breast Tumour Group. (BRAJCMF) BCCA Protocol Summary for Adjuvant Therapy for Premenopausal High Risk Breast Cancer Using Cyclophosphamide, Methotrexate and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 1999.
60. BC Cancer Agency Breast Tumour Group. (BRAJFEC) BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Cyclophosphamide, Epirubicin and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2005.

61. BC Cancer Agency Breast Tumour Group. (UBRAJFECED) BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Fluorouracil, Cyclophosphamide, and Docetaxel. Vancouver, British Columbia: BC Cancer Agency; 2006.
62. BC Cancer Agency Breast Tumour Group. (BRAVCAF) BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Cyclophosphamide, Doxorubicin, and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2004.
63. BC Cancer Agency Breast Tumour Group. (BRAVCMF) BCCA Protocol Summary for Palliative Therapy for Advanced Breast Cancer Using Cyclophosphamide, Methotrexate, and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2004.
64. BC Cancer Agency Breast Tumour Group. (BRINFCAF) BCCA Protocol Summary for Inflammatory Breast Cancer Using Cyclophosphamide, Doxorubicin, and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2004.
65. BC Cancer Agency Breast Tumour Group. (BRINCFEF) BCCA Protocol Summary for Inflammatory Breast Cancer Using Cyclophosphamide, Epirubicin, and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2005.
66. BC Cancer Agency Gastrointestinal Tumour Group. (GIENDO1) BCCA Protocol Summary for Palliative Therapy of Pancreatic Endocrine Tumours Using Carmustine and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2006.
67. BC Cancer Agency Gastrointestinal Tumour Group. (GIFFAD) BCCA Protocol Summary for Adjuvant Therapy for Stage III and High Risk Stage II Colon Cancer Using Leucovorin and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2006.
68. BC Cancer Agency Gastrointestinal Tumour Group. (GIPAJFF) BCCA Protocol Summary for Adjuvant Therapy for Resected Pancreatic Cancer Using Leucovorin and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2006.
69. BC Cancer Agency Breast Tumour Group. (BRAJCAFPO) BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Oral Cyclophosphamide, Doxorubicin, Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2004.
70. BC Cancer Agency Breast Tumour Group. (BRAJCEF) BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Cyclophosphamide, Epirubicin and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2005.
71. BC Cancer Agency Breast Tumour Group. (BRAJCMFPO) BCCA Protocol Summary for Adjuvant Therapy for Premenopausal High-Risk Breast Cancer Using (Oral) Cyclophosphamide, Methotrexate, and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 1999.
72. BC Cancer Agency Breast Tumour Group. (BRAVCMFPO) BCCA Protocol Summary for Palliative Therapy for Advanced Breast Cancer Using Cyclophosphamide (Oral), Methotrexate, and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2004.
73. BC Cancer Agency Breast Tumour Group. (BRLACEF) BCCA Protocol Summary for Locally Advanced Breast Cancer Using Cyclophosphamide, Epirubicin, and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2005.
74. BC Cancer Agency Breast Tumour Group. (BRAJCAF-G) BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Cyclophosphamide, Doxorubicin, Fluorouracil, and Filgrastim (G-CSF). Vancouver, British Columbia: BC Cancer Agency; 2004.
75. BC Cancer Agency Breast Tumour Group. (BRAJCEFG) BCCA Protocol Summary for Adjuvant Therapy for Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil, and Filgrastim (G-CSF). Vancouver, British Columbia: BC Cancer Agency; 2005.
76. BC Cancer Agency Breast Tumour Group. (BRINCFEFG) BCCA Protocol Summary for Inflammatory Breast Cancer Using Cyclophosphamide, Doxorubicin, Fluorouracil, and Filgrastim (G-CSF). Vancouver, British Columbia: BC Cancer Agency; 2005.
77. BC Cancer Agency Breast Tumour Group. (BRLACEFG) BCCA Protocol Summary for Inflammatory Breast Cancer Using Cyclophosphamide, Epirubicin, Fluorouracil, and Filgrastim (G-CSF). Vancouver, British Columbia: BC Cancer Agency; 2005.
78. BC Cancer Agency Genitourinary Tumour Group. (GUFUP) BCCA Protocol Summary for Combined Modality Therapy for Squamous Cell Cancer of the Genitourinary System Using Fluorouracil and Cisplatin. Vancouver, British Columbia: BC Cancer Agency; 2005.
79. BC Cancer Agency Head and Neck Tumour Group. (HNFUP) BCCA Protocol Summary for Advanced Head and Neck Cancer Using Cisplatin and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2005.
80. BC Cancer Agency Gastrointestinal Tumour Group. (UGIIRFUFA) BCCA Protocol Summary for Palliative Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, and Folinic Acid (Leucovorin). Vancouver, British Columbia: BC Cancer Agency; 2006.
81. BC Cancer Agency Gastrointestinal Tumour Group. (GIFUFA) BCCA Protocol Summary for Advanced Colorectal Cancer Using Leucovorin and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2006.
82. BC Cancer Agency Head and Neck Tumour Group. (HNCMT) BCCA Protocol Summary for Combined Chemotherapy (Carboplatin and Fluorouracil) and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Vancouver, British Columbia: BC Cancer Agency; 2001.
83. BC Cancer Agency Gastrointestinal Tumour Group. (GIGAI) BCCA Protocol Summary for Combined Modality Adjuvant Therapy for Completely Resected Gastric Adenocarcinoma Using Fluorouracil and Folinic Acid (Leucovorin) and Radiation Therapy. Vancouver, British Columbia: BC Cancer Agency; 2006.
84. BC Cancer Agency Head and Neck Tumour Group. (HNFUA) BCCA Protocol Summary for Combined Modality Therapy for Advanced Head and Neck Cancer Using Mitomycin, Fluorouracil, and Split Course Radiation Therapy. Vancouver, British Columbia: BC Cancer Agency; 2005.
85. BC Cancer Agency Gastrointestinal Tumour Group. (GIFUR2) BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Fluorouracil, Leucovorin, and Radiation Therapy. Vancouver, British Columbia: BC Cancer Agency; 2006.
86. BC Cancer Agency Gastrointestinal Tumour Group. (GIFUR3) BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Fluorouracil, Folinic Acid (Leucovorin), and Radiation Therapy. Vancouver, British Columbia: BC Cancer Agency; 2006.
87. BC Cancer Agency Gastrointestinal Tumour Group. (GIEFUP) BCCA Protocol Summary for Combined Modality Therapy for Locally Advanced Esophageal Cancer Using Cisplatin Infusional Fluorouracil and Radiation Therapy. Vancouver, British Columbia: BC Cancer Agency; 2006.

88. BC Cancer Agency Gastrointestinal Tumour Group. (GIRLAIFF) BCCA Protocol Summary for Pre-Operative Concurrent Chemotherapy and Radiotherapy and Post Operative Chemotherapy for Locally Advanced (Borderline Resectable or Unresectable) Rectal Adenocarcinoma (Interim Version). Vancouver, British Columbia: BC Cancer Agency; 2006.
89. BC Cancer Agency Gastrointestinal Tumour Group. (GIFUA) BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Infusional Fluorouracil, and Radiation Therapy. Vancouver, British Columbia: BC Cancer Agency; 2005.
90. Roderburg C, do O N, Fuchs R, et al. Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction. *Clin.Colorectal Cancer*. 2011;10(1):E6-9.
91. Hotta T, Takifuji K, Arii K, et al. Toxicity during I-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer. *Oncol.Rep*. 2005;14(2):433-439.
92. Fleming GF, Schilsky RL, Schumm LP, et al. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. *Ann.Oncol*. 2003;14(7):1142-1147.
93. Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of Chemotherapy. *Sem Onc* 2006;33(1):50-67.
94. Koren G, Beatty K, Seto A, et al. The effects of impaired liver function on the elimination of antineoplastic agents. *Ann Pharmacother* 1992;26:363-371.
95. Aronoff GR, Brier ME, Berns JS, Bennett W. The Renal Drug Book. Accessed on 20 April 2006. Available online at: <http://www.kdp-baptist.louisville.edu/renalbook/expand.asp?ID=1436>.